MYOV News and Press, Myovant Sciences Ltd. From 09/23/20

P rostate cancer and uterine fibroids disproportionately impact Black Americans; racial disparities are exacerbated by inequities in healthcare access and COVID-19 pandemic Myovant expands ongoing efforts to advance health equity with gran...

Myovant reports additional data from uterine fibroids study. Fortress Biotech reports start of AL Amyloidosis Phase 3 studies. Avita begins enrolment for vitiligo repigmentation pivotal study. For further details see: Myovant Reports Data, And Other News: The Good, Bad A...

Myovant Sciences (NYSE: MYOV ) presents one-year data on bone mineral density (BMD) from the Phase 3 LIBERTY program evaluating the safety and efficacy of once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uteri...

Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated women Findings presented at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event BASEL, Switzer...

Clovis reports positive data from TRITON clinical trial Clovis Oncology Inc. ( CLVS ) announced additional data from the Phase 2 TRITON2 study of its lead drug candidate Rubraca for treating metastatic castration-resistant prostate cancer harboring BRCA1/2 mutations. The data corroborated ...

The FDA accepts for review Myovant Sciences' (NYSE: MYOV ) marketing application seeking approval of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroid...

FDA sets target action date of June 1, 2021 BASEL, Switzerland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugo...

Myovant Sciences (NYSE: MYOV ) : Q1 GAAP EPS of -$0.37. Revenue of $33M Press Release More news on: Myovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news,

New Drug Application (NDA) for relugolix monotherapy tablet in advanced prostate cancer accepted for Priority Review by the FDA with target action date of December 20, 2020 NDA for relugolix combination tablet in uterine fibroids submitted in May 2020 Additional USD 200 million lo...

Sumitomo Dainippon Pharma ( OTCPK:DNPUF ) extends additional $200M low-interest, five-year term loan to Myovant Sciences (NYSE: MYOV ) , bringing its total financing support to $600M. More news on: Sumitomo Dainippon Pharma Co., Ltd., Myovant Sciences Ltd., Healthcare stocks n...